Cutaneous lupus erythematosus
Drug research and approvals for cutaneous lupus erythematosus: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 22, 2026, 22 studies of cutaneous lupus erythematosus are recruiting on ClinicalTrials.gov, and Health Canada has authorized 3 drug trials for it since 2013.
- Recruiting worldwide: 22
- Trials authorized in Canada: 3
- FDA orphan approvals: 0
- EU medicines: 0
- Study of Afimetoran in Adults With Cutaneous Lupus ErythematosusNCT07881120 · Phase 2 / Phase 3 · Beeline Medicines Corporation · starts Nov 3, 2026
- A Long-Term Extension (LTE) Study Of Enpatoran In Cutaneous Manifestations Of Lupus With Or Without Systemic Disease…NCT07840287 · Phase 3 · EMD Serono Research & Development Institute, Inc. · starts Oct 22, 2026
- A Study on the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Dose of SHR-7012 in Healthy…NCT07749651 · Phase 1 · Guangdong Hengrui Pharmaceutical Co., Ltd · starts Aug 19, 2026
- Rollover Study for Participants Who Have Completed a Previous Clinical Study With Anifrolumab (Saphnelo) and Clinically…NCT07691970 · Phase 3 · AstraZeneca · starts Aug 31, 2026
- A Study of Quinacrine in Participants With Cutaneous Lupus ErythematosusNCT07694336 · Phase 2 · Victoria Werth · starts Jun 30, 2026
- Study of S-4321 in Participants With an Autoimmune or Immune-mediated DiseaseNCT07455578 · Phase 1 · Seismic Therapeutic AU Pty Ltd · starts Jun 1, 2026
- Evaluate the Efficacy and Safety of ICP-488 in Subjects With Cutaneous Lupus Erythematosus (CLE) Double-blind StudyNCT07440537 · Phase 2 · Beijing InnoCare Pharma Tech Co., Ltd. · starts Apr 27, 2026
- A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2)NCT07355218 · Phase 3 · EMD Serono Research & Development Institute, Inc. · starts Apr 1, 2026
- A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic DiseaseNCT07332481 · Phase 3 · EMD Serono Research & Development Institute, Inc. · starts Mar 10, 2026
Phase 3 3
- LitifilimabC-type lectin domain family 4 member C inhibitor
- HydroxychloroquineFerriprotoporphyrin IX inhibitor
- AnifrolumabInterferon-alpha/beta receptor alpha chain antagonist
Phase 2 12 of 14
- Edecesertib
- EtanerceptTNF-alpha inhibitor
- TacrolimusFK506-binding protein 1A inhibitor
- ErgocalciferolVitamin D receptor agonist
- AlitretinoinRetinoid receptor agonist
- FilgotinibTyrosine-protein kinase JAK1 inhibitor
- MocravimodSphingosine 1-phosphate receptor Edg-1 agonist
- DovramilastPhosphodiesterase 4 inhibitor
- LanraplenibTyrosine-protein kinase SYK inhibitor
- DazukibartInterferon beta inhibitor
- CravacitinibTyrosine-protein kinase TYK2 negative allosteric modulator
- Niacinamide
Phase 1 or earlier 7
- TofacitinibJanus Kinase (JAK) inhibitor
- SirukumabInterleukin-6 inhibitor
- AMG-557ICOS ligand inhibitor
- PD-360324Macrophage colony-stimulating factor 1 inhibitor
- EnpatoranToll-like receptor 8 antagonist
- AfimetoranToll-like receptor 8 inhibitor
- Human immunoglobulin gReplacement therapy, immunomodulatory effects
How its trials ended
47 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 12 whose ending is known, 17% met their primary endpoint, 8% missed it and 75% stopped early.
- Completed, result not reported2349%
- Ongoing1021%
- Stopped: other or unclear49%
- Stopped: enrollment or feasibility36%
- Met its primary endpoint24%
- Status unknown24%
- Missed its primary endpoint12%
- Stopped: sponsor or business decision12%
- Stopped: funding12%
| Jun 25, 2025 | A phase 2b, randomized, double-blind, placebo-controlled study to assess the safety, tolerability, and efficacy of IMVT-1402 in participants with active…IMVT-1402 | Immunovant Sciences GmbH | Closed |
| Sep 14, 2022 | A 2-part seamless part a (phase 2)/part b (phase 3) randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of…BIIB059 | Biogen | Ongoing |
| Feb 12, 2021 | A randomized, double-blind, placebo controlled, proof of concept study assessing the efficacy and safety of the RIPK1-inhibitor SAR443122 in patients with…Eclitasertib (SAR443122) | Sanofi-Aventis Canada Inc | Ongoing |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA